US 11,684,622 B2
Deuterated RUC-4
Yatindra Joshi, North Wales, PA (US)
Assigned to CeleCor Therapeutics, Inc., Del Mar, CA (US)
Appl. No. 17/253,427
Filed by CeleCor Therapeutics, Inc., San Diego, CA (US)
PCT Filed Jun. 18, 2019, PCT No. PCT/US2019/037713
§ 371(c)(1), (2) Date Dec. 17, 2020,
PCT Pub. No. WO2019/246085, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/687,150, filed on Jun. 19, 2018.
Prior Publication US 2021/0361658 A1, Nov. 25, 2021
Int. Cl. A61K 31/519 (2006.01); A61K 31/122 (2006.01); A61K 31/37 (2006.01); A61K 31/4365 (2006.01); A61K 31/4465 (2006.01); A61K 31/616 (2006.01); A61K 31/702 (2006.01); A61K 31/727 (2006.01); A61K 38/12 (2006.01); A61K 38/48 (2006.01); A61K 39/395 (2006.01); C07D 513/04 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/122 (2013.01); A61K 31/37 (2013.01); A61K 31/4365 (2013.01); A61K 31/4465 (2013.01); A61K 31/616 (2013.01); A61K 31/702 (2013.01); A61K 31/727 (2013.01); A61K 38/12 (2013.01); A61K 38/482 (2013.01); A61K 39/3955 (2013.01); C07D 513/04 (2013.01); C07B 2200/05 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
each of Ra, Rb, Rc, Rd, R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13, R14, and R15 independently are hydrogen or deuterium;
provided that at least one of R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R12, R13, R14, and R15 is deuterium.